Search

Oxford Biomedica PLC

Cerrado

299 0.84

Resumen

Variación precio

24h

Actual

Mínimo

285.5

Máximo

300

Métricas clave

By Trading Economics

Ingresos

-32M

Ventas

51M

Margen de beneficio

-63.939

Empleados

861

EBITDA

-20M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+118.42% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

317M

Apertura anterior

298.16

Cierre anterior

299

Oxford Biomedica PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

23 abr 2025, 23:54 UTC

Acciones populares

Stocks to Watch: International Business Machines, Southwest Airlines, Robert Half

23 abr 2025, 23:23 UTC

Principales Noticias
Ganancias

SK Hynix Posts Strong First Quarter Earnings on AI Chip Demand

23 abr 2025, 21:06 UTC

Ganancias

Lam Research Notches Higher 3Q Profit and Revenue, Optimistic 4Q Outlook

23 abr 2025, 21:03 UTC

Ganancias

Texas Instruments Posts Increase in 1Q Sales, EPS

24 abr 2025, 00:00 UTC

Ganancias

Renesas Electronics 1Q Net Y26.01B Vs Net Y79.87B

24 abr 2025, 00:00 UTC

Ganancias

Renesas Electronics 1Q Net Y26.01B Vs Net Y79.87B

23 abr 2025, 23:47 UTC

Charlas de Mercado

Gold Rises Amid Lingering Uncertainty Over U.S.-China Trade War -- Market Talk

23 abr 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise as Fears About U.S. Tariffs Ease -- Market Talk

23 abr 2025, 23:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

23 abr 2025, 23:37 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

23 abr 2025, 23:36 UTC

Charlas de Mercado

Fed Should Have a 'High Bar' to Intervene in Markets, Hammack Says -- Market Talk

23 abr 2025, 23:21 UTC

Charlas de Mercado

Northern Star Bull Says Share Price Accounts for Operational Risks -- Market Talk

23 abr 2025, 23:00 UTC

Principales Noticias

South Korea's Economy Shrinks in 1Q Before Trump Tariffs Hit

23 abr 2025, 22:51 UTC

Ganancias

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

23 abr 2025, 22:50 UTC

Ganancias

SK Hynix 1Q Net KRW8.108T Vs. Net KRW1.917T >000660.SE

23 abr 2025, 22:49 UTC

Ganancias

SK Hynix 1Q Oper Pft KRW7.441T Vs. Pft KRW2.886T >000660.SE

23 abr 2025, 22:49 UTC

Ganancias

SK Hynix 1Q Rev KRW17.639T Vs. KRW12.430T >000660.SE

23 abr 2025, 22:32 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Energy Roundup: Market Talk

23 abr 2025, 22:32 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Woodside Appears Cornered Into 2Q Decision on Louisiana LNG -- Market Talk

23 abr 2025, 22:29 UTC

Charlas de Mercado
Ganancias

ServiceNow CEO Says Aptiv Deal Marks 2nd Largest in EMEA -- Market Talk

23 abr 2025, 22:18 UTC

Ganancias

CGN Power: 1Q Net Weighed by Fall in Electricity Prices, Higher R&D Expenses >1816.HK

23 abr 2025, 22:17 UTC

Ganancias

CGN Power 1Q Net CNY3.03B Vs. Net CNY3.60B >1816.HK

23 abr 2025, 22:17 UTC

Ganancias

CGN Power 1Q Rev CNY20.03B Vs. CNY19.18B >1816.HK

23 abr 2025, 21:57 UTC

Charlas de Mercado
Ganancias

ServiceNow Earnings, Guidance Soothe Fear of Slower Govt Business -- Market Talk

23 abr 2025, 21:48 UTC

Principales Noticias

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23 abr 2025, 21:14 UTC

Principales Noticias
Ganancias

Southwest Airlines Drops Forecast as Leisure Travelers Pull Back -- WSJ

23 abr 2025, 21:05 UTC

Ganancias

Texas Instruments Reports Strong Earnings. The Stock Is Rising but Tariffs Are Still a Risk. -- Barrons.com

23 abr 2025, 21:02 UTC

Principales Noticias

Huge Stock Swings Are the New Normal for Frazzled Investors -- WSJ

23 abr 2025, 20:51 UTC

Ganancias

Boeing Stock Surges on Earnings. There Is Still a Lot of Uncertainty Ahead. -- Barrons.com

23 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Oxford Biomedica PLC Esperado

Precio Objetivo

By TipRanks

118.42% repunte

Estimación a 12 meses

Media 649.792 GBX  118.42%

Máximo 800 GBX

Mínimo 500 GBX

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Oxford Biomedica PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.